Skip to content
Clinical Trials – home

Find therapies in clinical trials near you – page 2

recruiting
3 974
countries
28
conditions
2 106

80 trials match your criteria

Neuroblastoma

Recruiting

Study on Stem Cell Transplantation and Immunotherapy with Rituximab, Dinutuximab Beta, and Drug Combination for Patients with High-Risk Relapsed Neuroblastoma

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:0–17 years · 18–64 years
  • Substances:Dinutuximab Beta

B-cell lymphoma+2

Recruiting

Study on Immunotherapy with HSP-CAR19M and Drug Combination for Adults with B-cell Non-Hodgkin Lymphoma

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:HSP-CAR19M

Study on the Effectiveness of Gilteritinib and Drug Combination for Patients with Relapsed or Refractory Acute Myeloid Leukemia

Registered drugNo placebo
Countries:CzechiaCzechia
  • Participants:18–64 years · 65+ years
  • Substances:Amsacrine

Study of DDCART-CD19 cells with cyclophosphamide and fludarabine for children and young adults (up to 39 years) with recurrent acute leukemia after stem cell transplant

Registered drugNo placebo
Countries:GreeceGreece
  • Participants:0–17 years · 18–64 years
  • Substances:Cyclophosphamide

Study of Ziftomenib with Chemotherapy for Children with Relapsed or Refractory Acute Leukemia

Registered drugNo placebo
Countries:AustriaAustria
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine

Neoplasm+2

Recruiting

Study Comparing ANV419 and High Dose IL2 in Adoptive Cell Therapy for Patients with Melanoma, Non-Small Cell Lung Cancer, and Cervical Cancer

Registered drugNo placebo
Countries:DenmarkDenmark
  • Participants:18–64 years · 65+ years
  • Substances:Aldesleukin

Leukaemia

Recruiting

Study on the Safety and Effectiveness of Venetoclax with Fludarabine, Amsacrine, and Cytarabine for Patients with MDS, CMML, or Secondary AML Undergoing Stem Cell Transplantation

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Allopurinol

Study of Azacitidine and Drug Combination Before Stem Cell Transplantation in Patients with High-Risk Myelodysplastic Syndrome

Registered drugNo placebo
Countries:ItalyItaly
  • Participants:18–64 years · 65+ years
  • Substances:Azacitidine

Study on the Safety and Effectiveness of CABA-201, Fludarabine Phosphate, and Cyclophosphamide in Patients with Active Systemic Lupus Erythematosus

Registered drugNo placebo
Countries:FranceFrance
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:CABA-201

Study on the Safety of CD19 CAR-T Cells, Cyclophosphamide, and Fludarabine in Adults with Refractory or Relapsed Acute Myeloid Leukemia Expressing CD19

Registered drugNo placebo
Countries:FranceFrance
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide

Study on Treating Acute Myeloid Leukemia in Children and Adolescents Using Daunorubicin, Mitoxantrone, and a Drug Combination

Registered drugNo placebo
Countries:BelgiumBelgium
  • Participants:0–17 years · 18–64 years
  • Substances:Cytarabine

Study on Fludarabine, Melphalan, and Radiation for Patients with High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia Preparing for Stem Cell Transplant.

Registered drugNo placebo
Countries:SpainSpain
  • Participants:18–64 years · 65+ years
  • Substances:Cyclophosphamide
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.